Sage Therapeutics Does Not Anticipate Receipt Of Any Milestone Payments From Collaborations In Remainder Of 2024; Anticipates ZULRESSO Use Will Continue To Decrease And Has Decided To No Longer Make ZULRESSO Commercially Available As Of December 31, 2024
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics announced it does not expect any milestone payments from collaborations for the rest of 2024. Additionally, the company anticipates a continued decrease in the use of ZULRESSO and plans to cease its commercial availability by the end of 2024.
October 29, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics will not receive any milestone payments from collaborations for the rest of 2024. The company also plans to discontinue ZULRESSO by the end of 2024 due to declining use.
The lack of expected milestone payments and the decision to discontinue ZULRESSO, a product with declining use, suggest potential revenue challenges for Sage Therapeutics. This could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100